XML 68 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Goodwill [Roll Forward]    
Beginning balance $ 55,197,000 $ 46,737,000
Percentage payments on collections of net sales of DepoBupivacaine products, including EXPAREL 6,843,000 8,460,000
Ending balance 62,040,000 $ 55,197,000
Upon first commercial sale in the United States    
Goodwill    
Milestone payments for EXPAREL agreed in connection with acquisition 10,000,000  
Upon first commercial sale in a major EU country (United Kingdom, France, Germany, Italy and Spain)    
Goodwill    
Milestone payments for EXPAREL agreed in connection with acquisition 4,000,000  
When annual net sales collected reach $100.0 million    
Goodwill    
Milestone payments for EXPAREL agreed in connection with acquisition 8,000,000  
Annual net sales threshold 100,000,000  
When annual net sales collected reach $250.0 million    
Goodwill    
Milestone payments for EXPAREL agreed in connection with acquisition 8,000,000  
Annual net sales threshold 250,000,000  
When annual net sales collected reach $500.0 million    
Goodwill    
Milestone payments for EXPAREL agreed in connection with acquisition 32,000,000  
Annual net sales threshold 500,000,000  
Skye Pharma Holding Inc. [Member]    
Goodwill [Roll Forward]    
Total Milestone Payments Yet to be Paid for Sale of Product in Connection with Acquisition $ 36,000,000